Literature DB >> 9024750

Relation between amiodarone and desethylamiodarone plasma concentrations and ventricular defibrillation energy requirements.

E G Daoud1, K C Man, L Horwood, F Morady, S A Strickberger.   

Abstract

The main finding of this prospective, controlled study is that amiodarone and desethylamiodarone plasma concentrations < 1 mg/L are associated with a 23% increase in the acute defibrillation energy requirement and with a 31% increase in the requirement for a subcutaneous patch or array. The defibrillation energy requirement does not correlate with the plasma concentrations of amiodarone, desethylamiodarone, amiodarone plus desethylamiodarone, or with the duration or daily dosage of amiodarone therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024750     DOI: 10.1016/s0002-9149(96)00689-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Evaluation of defibrillation safety margin in modern implantable cardioverter defibrillators after administration of amiodarone.

Authors:  Julia Köbe; Florian Reinke; Dirk G Dechering; Günter Breithardt; Lars Eckardt
Journal:  Clin Res Cardiol       Date:  2011-11-05       Impact factor: 5.460

2.  Incidence and clinical predictors of low defibrillation safety margin at time of implantable defibrillator implantation.

Authors:  Zhongwei Cheng; Mintu Turakhia; Ronald Lo; Anurag Gupta; Paul C Zei; Henry H Hsia; Amin Al-Ahmad; Paul J Wang
Journal:  J Interv Card Electrophysiol       Date:  2012-03-06       Impact factor: 1.900

3.  Electrical storms in an ICD-recipient with 429 delivered appropriate shocks: therapeutic management with antiarrhythmic drug combination.

Authors:  Athanasios G Manolis; Apostolos G Katsivas; Charis Vassilopoulos; Costas G Tsatiris
Journal:  J Interv Card Electrophysiol       Date:  2002-02       Impact factor: 1.900

Review 4.  Effect of drugs on defibrillation capacity.

Authors:  Anna Legreid Dopp; John M Miller; James E Tisdale
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.